Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC5A2 | P31639 | 8/20 | 0.42 |
| ▸ | SLC5A1 | P13866 | 2/20 | 0.42 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.42 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.42 |
| ▸ | GLA | P06280 | 1/20 | 0.42 |
| ▸ | GAA | P10253 | 1/20 | 0.42 |
| ▸ | POLB | P06746 | 1/20 | 0.41 |
| ▸ | SELL | P14151 | 1/20 | 0.40 |
| ▸ | SELP | P16109 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6784360 | 1.00 | SLC5A2 (0.42) | SLC5A2SLC5A1KDM4EALDH1A1GLA | |
| SCHEMBL6934645 | 1.00 | SLC5A2 (0.42) | SLC5A2SLC5A1KDM4EALDH1A1GLA | |
| SCHEMBL6932964 | 0.90 | KDM4E (0.45) | SLC5A2SLC5A1KDM4EALDH1A1GLA | |
| SCHEMBL6796400 | 0.90 | KDM4E (0.45) | SLC5A2SLC5A1KDM4EALDH1A1GLA | |
| SCHEMBL8973945 | 0.86 | PYGL (0.43) | SLC5A2SELLSELP | |
| SCHEMBL5878336 | 0.84 | UMPS (0.44) | SLC5A2KDM4EALDH1A1GLAGAA | |
| SCHEMBL6789974 | 0.77 | SLC5A2 (0.42) | SLC5A2SLC5A1POLB | |
| SCHEMBL6789968 | 0.77 | SLC5A2 (0.42) | SLC5A2SLC5A1POLB | |
| SCHEMBL6787977 | 0.77 | L3MBTL1 (0.44) | SLC5A2SLC5A1SELLSELP | |
| SCHEMBL6790315 | 0.77 | L3MBTL1 (0.44) | SLC5A2SLC5A1SELLSELP |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20040266723-A1 | Antiviral agents for treatment of Flaviviridae infections | PHARMASSET, INC. | 2004-12-30 | — | — | US | disclosed |
| EP-1366055-A2 | ANTIVIRAL AGENTS FOR TREATMENT OF FLAVIVIRIDAE INFECTIONS | Pharmasset Limited (BB) | 2003-12-03 | — | — | EP | disclosed |
| WO-2002048165-A2 | ANTIVIRAL AGENTS FOR TREATMENT OF FLAVIVIRIDAE INFECTIONS | PHARMASSET LTD. (BB) | 2002-06-20 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040266723-A1 | Antiviral agents for treatment of Flaviviridae infections | HAVCR2, MAVS, EIF2AK2 | SLC5A2 309/4885SLC5A1 155/4885KDM4E 1744/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.